Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorChristopher C. Thompson, MD, MSc

About this trial

Gastric myotomy has been performed for several years as a means of addressing chronic stenosis after sleeve gastrectomy and treating gastroparesis. The Pylorus Sparing Antral Myotomy (PSAM) technique has the opposite effect by leaving the pylorus intact and extending the myotomy proximally to the distal gastric body. PSAM was initially combined with ESG and shown to delay gastric emptying and provide greater weight loss without impacting tolerability (GCSI score) or the safety profile of the procedure (2 DDW GEM abstracts). PSAM has not been evaluated alone, without concomitant ESG. Since delayed gastric emptying alone is known to promote weight loss, it is thought that PSAM alone (without ESG) may provide similar efficacy, while reducing procedure time and adverse events. There have been no clinical studies that investigate the efficacy of PSAM independent of ESG. This pilot study aims to address this lack of information by evaluating the safety, tolerability, and short-term efficacy of PSAM, in addition to exploring its impact on gastric physiology. This will also provide data that may be used in designing a larger clinical trial.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

subjects must be 18-70 years of age

eligible for endoscopic and surgical weight loss procedures

body mass index (BMI) greater than 35 kg/m2

Individuals must be in excellent mental health

Disqualifiers

untreated H. pylori infection

gastroparesis

active smoking

an ongoing or a history of treatment with opioids in the last 12 months prior to enrollment

Trial population

Adults in the Center for Weight Management and Wellness program at Brigham and Women's Hospital with a BMI \>35 kg/m2 who are pre-qualified by their insurance as recommended by their specialist to undergo an endoscopic bariatric procedure.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • PSAM Treatment Patients

    Procedure/Surgery

    PSAM is a pylorus-sparing antral myotomy performed under general anesthesia. Endoscopic myotomy is then performed applying the principles of submucosal endoscopy and techniques used during gastric per-oral endoscopic myotomy (G-POEM). A submucosal bleb is created proximal to the pylorus. A longitudinal mucosal incision is made with an endoscopic knife. The endoscope is then introduced into the submucosal space, and the knife is used to dissect the submucosal fibers. Antral myotomy is performed starting proximal to the pyloric ring extending to the mucosal access site. The myotomy entails cutting of the inner circular and oblique muscle bundles or may be full thickness at the discretion of the endoscopist. The mucosal entry is then closed using endoscopic suturing or clips.

Treatment groups

30 Participants
are divided into 3 treatment groups
Group A: PSAM Treatment Patients with no prior endoscopic bariatric therapies1 intervention
Group B: PSAM Treatment Patients with prior primary endoscopic bariatric therapies1 intervention
Group C: PSAM Treatment Patients with prior revision endoscopic bariatric therapies1 intervention

Trial outcomes

Primary outcomes

1

Weight change compared to baseline

Percent total body weight loss

Time frame
Screening, Procedure day, 1 month, 3 month, 6 month, 9 month, 12 months
2

Adverse Events

Changes to health compared to baseline

Time frame
Procedure day, 1 month, 3 month, 6 month, 9 month, 12 months
3

Change in tolerability from procedure day to 12 months

How the subjects feel after the procedure based on pain scale and AE's

Time frame
Procedure day, 1 month, 3 month, 6 month, 9 month, 12 months

Secondary outcomes

1

Change in Quality of Life compared to baseline

Overall quality of life questionnaire

Time frame
Screening, 1 month, 3 month, 6 month, 9 month, 12 months
2

Gastric Emptying compared to baseline

Gastric emptying using a gastric emptying breath test (GEBT)

Time frame
Screening, 6 months, 12 months
3

Ghrelin levels compared to baseline

Laboratory analysis of blood samples to test ghrelin levels

Time frame
Screening, 6 months, 12 months
4

Insulin levels compared to baseline

Laboratory analysis of blood samples to test insulin metabolic profiles

Time frame
Screening, 6 months, 12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Christopher C. Thompson, MD, MSc

Lead sponsor

Brigham and Women's Hospital

Sponsor institution